Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. - Wikidata - awgldk - TriplyDB

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.

http://www.wikidata.org/entity/Q42970953

about

Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation.Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Recent advances in treating Parkinson's disease.Preclinical jockeying on the translational track of adenosine A2A receptors.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease Caffeine for treatment of Parkinson disease: a randomized controlled trial.Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.Caffeine consumption and risk of dyskinesia in CALM-PD.Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Modulation of A₂a receptor antagonist on D₂ receptor internalization and ERK phosphorylation.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.Future treatments for Parkinson's disease: surfing the PD pipeline.Istradefylline for the treatment of Parkinson's disease.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Adenosine A2A antagonists in Parkinson's disease: what's next?Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Non-dopaminergic treatments for motor control in Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.Dyskinesias in Parkinson's disease: views from positron emission tomography studies.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.The safety of istradefylline for the treatment of Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.Promising therapeutic agents for the treatment of Parkinson's disease.PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

P2860

Q27324174-C46754BB-09E6-480A-8E2F-50C7F2D4B86B Q29346490-B82B50FD-4A7F-4A4A-96F9-4327406FA91C Q34123200-1552E1E6-4CA4-4777-8256-05DF22239C53 Q34414817-89C77699-BB0F-4F5E-8C12-A67771AE4BCA Q34554401-79CCE5D7-8292-4776-B0D3-AE0C136EC6F0 Q34777609-AD449036-2437-4926-A406-BB979CDEB55D Q35489240-52FA3F4B-CA3A-48F4-8047-ABB8196ED058 Q35614156-DC41F708-9F8A-4351-90B2-BA5FBA908F14 Q35781883-8DCACC07-389F-4498-AAA0-BCB732C4B5FA Q36057652-78D759BC-D718-49B0-A2DC-176DF7B1B516 Q36149963-F36D14E3-9A6E-47DE-A950-6658E2DE685B Q36165527-412D9751-E73E-4EA3-89F4-03EAC6E1066A Q36717838-98F8EF09-AB19-4942-B6D0-7493DCE9F4B2 Q37348458-A6BEBC91-1E82-4A16-8A2B-AE1084D843E8 Q37506507-B68EBB30-CF31-4849-92C8-79B0BDCED079 Q37727738-A52D1C55-B0E0-445A-9313-C77481AC28B7 Q37844573-A1A19259-EAAC-4F43-AC1D-A1264CB4E062 Q37902895-1EEAD84A-8B1F-4132-AC7E-3099169A6885 Q37950428-CE05104E-91C8-435C-873F-007D13D5CEF9 Q37965615-B33E5E55-7E73-4063-8FAA-A7F7AAF142A7 Q37974709-7537426C-F4E7-40E5-8F8F-15C9E4CDA191 Q38010070-34B27706-C451-4064-B687-F59EBC5F23F8 Q38103966-446345F6-4536-4841-9E82-CA1E3A2EB861 Q38126817-5FC123C1-882B-484C-A7CC-E04B0C14458E Q38156760-747BD1FB-EFA8-4FDA-B4F6-184D642C2E20 Q38169996-B3AEC931-8BE4-4E67-A9F1-E98054C0518E Q38170421-679C5522-667B-44F6-82AB-B09648B9D43D Q38182651-8F65B5D0-CD30-47D0-866F-7776CD1A0036 Q38199744-81716BD2-86F5-4029-8320-4EE05992DA14 Q38200930-85857E86-DB0F-46EC-95E1-30524152C52D Q38237288-EBF388B0-59E3-4EEF-80DA-C44A4868BCBC Q38284574-CDB1692F-B2B3-40BE-97C5-91E1937F1521 Q38353204-2F313D9D-44DF-41C4-BA60-EEE0B18201C1 Q38355582-DBC702A3-9689-4BFE-8E98-7085B62A01CE Q38395423-4F2D4FB6-8ECF-451F-B9D6-F4201F016967 Q38478999-65CDD7EA-FB52-4E8A-9FBA-01733C5AC33F Q38658203-30FA2D12-CC8C-4EB1-93AE-D80A696446D8 Q38691042-67187474-0394-4FB5-AAAB-B97D58FE2570 Q38767711-529311A7-F28D-4501-83D3-91A49E6FE0E5 Q42369736-43AD018A-D0AB-49EF-AC60-03BC43238809

P2860

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.

http://www.wikidata.org/entity/Q42970953

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Clinical efficacy of istradefy ...... randomized, controlled study.

@en

Clinical efficacy of istradefy ...... randomized, controlled study.

@nl

type

label

Clinical efficacy of istradefy ...... randomized, controlled study.

@en

Clinical efficacy of istradefy ...... randomized, controlled study.

@nl

prefLabel

Clinical efficacy of istradefy ...... randomized, controlled study.

@en

Clinical efficacy of istradefy ...... randomized, controlled study.

@nl

P1433

Q42970953-DD3D3E47-F4B6-4CA3-BBC6-9105636560EB

P1476

Q42970953-BDC77537-36A6-4F95-A1B8-EB2E9D2AA5AB

P2093

Q42970953-1CD7E4C4-9003-4E95-8D2A-EF072C13D998

Q42970953-4317B900-ADB9-4B37-A8EB-C7A52BEC1FDD

Q42970953-8CB69BB5-942C-4916-B25C-D20627BEEBCF

Q42970953-ECC7BA67-C4D7-49D6-945F-E5215EDD219D

Q42970953-F31A95BA-A175-4CFD-8811-0FAEB9BE23C0

P2860

Q42970953-001A3D49-ACC2-4B39-83B0-C647C7CDB90E

Q42970953-21344130-1BFF-43C9-93AB-2C5A3A62FBA8

Q42970953-323F19AF-A314-450F-B66C-54342B77FD80

Q42970953-3AD29C12-AEB6-4560-9749-0CC8D080D6AC

Q42970953-5AC40EF7-AA80-4E4E-ABC8-8508C4C97C5F

Q42970953-5EDD58FD-CA6F-4046-B63B-E5763AEC1A75

Q42970953-68F0C645-A093-41ED-A44F-52BE074E2859

Q42970953-6B962065-5FB2-4519-8269-C251F28A8BBE

Q42970953-7497041A-B7FC-4F02-9A85-638B0C2CFA72

Q42970953-836DE3F6-FC9A-4B68-AE00-6F8EA6A97512

P304

Q42970953-9E759196-DADD-43AB-AF15-80D444A46E9B

P31

Q42970953-5174F7D8-72FE-4146-8105-E7D80A4601B1

P356

Q42970953-907892EB-AD8F-4244-90DB-A8F09B7C8981

P407

Q42970953-36747422-D3CD-45CC-899D-B778F1FC7ACA

P433

Q42970953-8B96EDCB-0D55-496A-8A1C-A71872A0B876

P478

Q42970953-305EF7CD-19F6-478F-A215-3CCAE8885D70

P50

Q42970953-5ADCA328-4ED6-46D7-A053-98D6E0274F77

P577

Q42970953-C8D48A45-8373-4CFA-AAF3-E344716B2415

P698

Q42970953-7AD73C41-C50E-48FD-B6D0-79DCC814203E

P921

Q42970953-66F0EF90-877B-4281-976C-45E0324EFDC6

P356

P1433

Movement Disorders

P1476

Clinical efficacy of istradefy ...... randomized, controlled study.

@en

P2093

Japanese Istradefylline Study Group

http://www.w3.org/2001/XMLSchema#string

Kazuko Hasegawa

http://www.w3.org/2001/XMLSchema#string

Mitsutoshi Yamamoto

http://www.w3.org/2001/XMLSchema#string

Sadako Kuno

http://www.w3.org/2001/XMLSchema#string

Tomoyoshi Kondo

http://www.w3.org/2001/XMLSchema#string

P2860

A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Parkinson's disease: mechanisms and models

Primate models of movement disorders of basal ganglia origin

Limitations of current Parkinson's disease therapy.

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease.

Neuroinflammatory processes in Parkinson's disease.

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.

P304

1437-1443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23107

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Yoshikuni Mizuno

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20629136

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease